Mehdi H. Hamadani, MD

Professor

view physician profile

Locations

Froedtert Hospital
Clinical Cancer Center - Froedtert Hospital
Cancer Center - Moorland Reserve Health Center

Specialties

Hematology
Medical Oncology

Languages

English, Urdu, Hindi, Punjabi

Clinical Cancer Center - Froedtert Hospital

(414) 805-0505

Moorland Reserve Health Center

(262) 798-7200

Education

MD - Doctor of Medicine

Biography

Mehdi Hamadani, MD, is A a professor of medicine at the Medical College of Wisconsin, Division of Hematology & Oncology, specializing in lymphoma, and bone marrow transplantation. Dr. Hamadani serves as the Director of the Adult Blood and Marrow Transplant Program (BMT) at Froedtert Hospital. He graduated from King Edward Medical College (with honors) in Pakistan in 2001, he then completed his internal medicine residency at Oklahoma University Health Sciences Center and a Fellowship in Hematology and Oncology at The Ohio State University. He received the James V. Warren Award for Accomplishments as The Most Outstanding Research Fellow, during his fellowship.

Research Interests

Dr. Hamadani has authored over 200 peer-reviewed publications, and has been invited as a speaker for several national and international meetings. He is the recipient of Conquer Cancer Foundation of ASCO Career Development Award and ASBMT New Investigator Award. Dr. Hamadani has also received several Best Attending Physician, Outstanding Teacher, Press Ganey Top Provider and Best Doctors in America Awards. His clinical research focuses on lymphoid malignancies and hematopoietic cell transplantation. Dr. Hamadani is board certified in Hematology and Medical Oncology.

Autologous Transplant or CAR-T as Consolidation Options in MYC Rearranged Large B-Cell Lymphoma Patients in Remission After Salvage Treatments.

(Furqan F, Ahn KW, Kaur M, Patel J, Ansell S, Awan FT, Baird J, Bezerra E, Farooq U, Fung H, Khurana A, Lekakis L, Lutfi F, McCarty J, Mukherjee A, Nath R, Romancik J, Schuster SJ, Smith M, Winter A, Turtle C, Sauter C, Shadman M, Herrara A, Hamadani M.) Am J Hematol. 2025 Jul;100(7):1152-1162 PMID: 40231369 SCOPUS ID: 2-s2.0-105002610922 04/15/2025
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation.

(Al Malki MM, Bo-Subait S, Logan B, Olson J, Kou J, Smith S, Leckrone E, Wu J, Stefanski HE, Auletta JJ, Spellman SR, Malmberg C, Askar M, Cusatis R, Shaffer BC, Modi D, Khimani F, Gooptu M, Hamadani M, Madbouly A, Maiers M, Fingerson S, Cook R, Ballen K, Loren A, Larkin K, Arai S, Qayed M, Choi SW, Broglie L, Shaw BE, Devine SM, Jimenez Jimenez AM.) J Clin Oncol. 2025 Jun 16:JCO2500856 PMID: 40523209 SCOPUS ID: 2-s2.0-105008736226 06/16/2025
Clinical practice recommendations on the role of allogeneic hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy in patients with chronic lymphocytic leukemia on behalf of the American Society for Transplantation and Cellular Therapy.

(Kharfan-Dabaja MA, Kumar A, Pinilla-Ibarz J, Brown JR, Shadman M, Awan FT, Kenderian SS, Siddiqi T, Abramson JS, Al-Juhaishi T, Brander DM, Coombs CC, Furman RR, Jain N, Khan N, Saba NS, Collins JM, Beitinjaneh A, Stephens DM, Woyach J, Hamadani M.) Transplant Cell Ther. 2025 Jun 11 PMID: 40514010 06/14/2025
Real-world treatment of large B-cell lymphoma with chimeric antigen receptor T-cell therapy after loncastuximab tesirine: a plain language summary.

(Hamadani M, Lucero M, DeVos JD, Chen L.) Future Oncol. 2025 Jun;21(13):1585-1600 PMID: 40444351 PMCID: PMC12140443 05/30/2025
How we treat mantle cell lymphoma with cellular therapy in 2025: the European and American perspectives.

(Dreger P, Ahmed S, Bazarbachi A, Dietrich S, Fenske TS, Ghosh N, Hermine O, Hamadani M.) Bone Marrow Transplant. 2025 Jun;60(6):759-768 PMID: 40229536 PMCID: PMC12151868 04/15/2025
Setting up a Chimeric Antigen Receptor T Cell Therapy Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation.

(Ahmed SO, El Fakih R, Kharfan-Dabaja MA, Syed F, Mufti G, Chabannon C, Rondelli D, Mohty M, Al Ahmari AA, Gauthier J, Ruella M, Perales MA, Hashmi S, Alfraih F, Ghorashian S, Alzahrani M, Abba Z, Koh M, Pasquini M, Ruggeri A, Garderet L, Albabtain A, Weisdorf D, Greinix H, Samarkandi H, Hamad N, Atsuta Y, Hamadani M, Hari P, Majhail NS, Greco R, Alzahrani H, Sureda A, Yakoub-Agha I, Alahmari AD, Niederwieser D, Aljurf M.) Transplant Cell Ther. 2025 May 23 PMID: 40414351 SCOPUS ID: 2-s2.0-105008926778 05/26/2025
Accurate prediction of absolute prokaryotic abundance from DNA concentration.

(Wirbel J, Andermann TM, Brooks EF, Evans L, Groth A, Dvorak M, Chakraborty M, Palushaj B, Reynolds GZM, Porter IE, Al Malki M, Rezvani A, Gooptu M, Elmariah H, Runaas L, Fei T, Martens MJ, Bolaños-Meade J, Hamadani M, Holtan S, Jenq R, Peled JU, Horowitz MM, Poston KL, Saber W, Kean LS, Perales MA, Bhatt AS.) Cell Rep Methods. 2025 May 19;5(5):101030 PMID: 40300608 PMCID: PMC12146642 SCOPUS ID: 2-s2.0-105003827989 04/30/2025
Impact of Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 years and Older: An Update from BMT CTN 1703.

(Abedin SM, Martens MJ, Bolaños-Meade J, Al Malki MM, Lian Q, Runaas L, Elmariah H, Gooptu M, Larkin K, Shaffer BC, Loren AW, Solh MM, Alousi AM, Jamy O, Perales MA, Rezvani AR, Bhatt AS, El Jurdi N, Yao JM, Applegate K, Kean LS, Efebera YA, Reshef R, Clark WB, Leifer E, Saber W, Horowitz MM, Jones RJ, Holtan SG, Hamadani M.) Blood Adv. 2025 Apr 30 PMID: 40305657 04/30/2025
Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study.

(Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, Godwin JE, Reagan PM, Wagner-Johnston ND, Essell JH, Nath R, Solomon SR, Champion R, Licitra E, Fanning S, Gupta NK, Chow VA, Yuan B, Yang Z, Ogasawara K, Thorpe J, Gordon LI.) Blood Adv. 2025 Apr 30 PMID: 40305658 04/30/2025
ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and Sézary syndrome.

(Goyal A, O'Leary D, Dabaja B, Weng WK, Zain J, Cutler C, Guitart J, Kim YH, Geskin LJ, Hoppe RT, Wilson LD, Beaven AW, Horwitz S, Allen PB, Barta SK, Bohjanen K, Brammer JE, Carter JB, Comfere N, DeSimone JA, Dusenbery K, Duvic M, Huen A, Jagadeesh D, Kelsey CR, Khodadoust MS, Lechowicz MJ, Mehta-Shah N, Moskowitz AJ, Olsen EA, Poh C, Pro B, Querfeld C, Sauter C, Sokol L, Sokumbi O, Wilcox RA, Zic JA, Gru A, Hamadani M, Foss F.) J Am Acad Dermatol. 2025 Apr 06 PMID: 40199382 04/09/2025
Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma.

(Shah NN, Colina AS, Johnson BD, Szabo A, Furqan F, Kearl T, Schneider D, Vargas-Cortes M, Schmeling JL, Dwinell MB, Palen K, Longo W, Hematti P, Zamora AE, Hari P, Bucklan D, Cunningham A, Hamadani M, Fenske TS.) J Clin Oncol. 2025 Mar 31:JCO2402158 PMID: 40163793 03/31/2025
Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers.

(Voorhees TJ, McLaughlin EM, Torka P, Florindez J, Kim NH, Moyo TK, Reves H, Sumransub N, Deshpande S, Rose A, Duarte C, Faisal MS, Hamid S, Subbiah S, Ayyappan S, Shea L, Cortese M, Patel K, Major A, Saeed H, Svoboda J, Desai S, Geethakumari PR, Hamadani M, Grover N, Epperla N.) Blood Cancer J. 2025 Mar 26;15(1):45 PMID: 40140364 PMCID: PMC11947194 03/27/2025